17,261 trials
Idiopathic Restless Legs Syndrome
Primary: Change of International Restless Legs Syndrome Study Group Rating Scale (IRLS) Score From the Baseline to the End of Titration/Maintenance Period — -9.8; -10.7; -14.4…
Fabry Disease
Primary: Change From Baseline to Week 16 (EOS) in Urine Gb3 Levels — -28.68 (nmol/g creatinine)
Multiple Myeloma
Primary: Maximum Tolerated Dose (MTD) — 20 mg LBH589
Systemic Lupus Erythematosus · SLE · Lupus
Primary: Percent of Participants With an IFN Alpha Signature Response at Week 12 — 36.8; 23.5; 27.8; 25.7 Percent of participants — p=0.53
Pulmonary Disease, Chronic Obstructive
Primary: Number of Participants With Any Adverse Event (AE) or Any Serious Adverse Event (SAE) — 6; 9; 8; 4 Participants
Lymphocytic Leukemia, Chronic
Primary: Objective Response Rate (ORR) — 48.8; 66.7 Percentage of participants — p=0.0779
Candidiasis, Esophageal · Candidiasis, Invasive · Aspergillosis
Primary: Percentage of Participants With an Overall Favorable Response to Therapy — 66.7; 62.5 Percentage of Participants
Orthostatic Hypotension · Spinal Cord Injury
Primary: Blood Pressure — 120; 112; 117; 109 mmHg
Idiopathic Restless Legs Syndrome
Primary: The Incidence and Severity of Adverse Events (AEs), Vital Signs, and Laboratory Parameters — 175; 139; 5; 1 participants
Lung Adenocarcinoma · Lung Adenosquamous Carcinoma · Malignant Pericardial Effusion
Primary: 18 Weeks Progression Free Survival (PFS) Rate — 52; 69 percentage of participants
Type II Hyperlipidemia
Primary: Percent Change in HDL-C From Baseline — 3.2; 84.2; 122.1; 160.6 percent change from baseline
Multiple Myeloma
Primary: International Myeloma Working Group (IMWG) Response Criteria — 8; 4; 7; 19 participants
Extensive-Stage Small Cell Lung Cancer
Primary: Progression Free Survival Rate — 13 percentage of patients with PFS
Cervical Ripening · Induction of Labor
Primary: Proportion of Women Delivering Vaginally — 63.75; 66.67; 76.00 percentage of participants — p=0.057
Type 2 Diabetes Mellitus
Primary: Number of Participants With a Reduction of HbA1c of >0.5% — 0; 0 Participants